Semi-Solid Dosage Contract Manufacturing

Global Semi-Solid Dosage Contract Manufacturing Market to Reach US$35.3 Billion by 2030

The global market for Semi-Solid Dosage Contract Manufacturing estimated at US$18.9 Billion in the year 2024, is expected to reach US$35.3 Billion by 2030, growing at a CAGR of 11.0% over the analysis period 2024-2030. Topical, one of the segments analyzed in the report, is expected to record a 10.3% CAGR and reach US$18.1 Billion by the end of the analysis period. Growth in the Transdermal segment is estimated at 12.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$5.1 Billion While China is Forecast to Grow at 14.8% CAGR

The Semi-Solid Dosage Contract Manufacturing market in the U.S. is estimated at US$5.1 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$7.2 Billion by the year 2030 trailing a CAGR of 14.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.0% and 9.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.7% CAGR.

Global Semi-Solid Dosage Contract Manufacturing Market – Key Trends & Drivers Summarized

Why Is Semi-Solid Dosage Contract Manufacturing Gaining Traction In The Pharmaceutical Industry?

The semi-solid dosage contract manufacturing market is expanding as pharmaceutical companies increasingly outsource production to specialized contract manufacturers. Semi-solid formulations, including creams, gels, ointments, and pastes, require advanced formulation expertise, sophisticated equipment, and stringent regulatory compliance. Contract manufacturing organizations (CMOs) offer cost-effective solutions, enabling pharmaceutical companies to focus on research, marketing, and distribution while ensuring high-quality manufacturing. The growing demand for dermatological treatments, transdermal drug delivery systems, and topical pain relief medications is driving the need for specialized semi-solid formulation expertise. Additionally, the rise of personalized medicine and controlled-release formulations is expanding the scope of semi-solid dosage contract manufacturing.

What Technological Innovations Are Advancing Semi-Solid Dosage Manufacturing?

Advancements in emulsification technology, microencapsulation, and lipid-based drug delivery systems are improving the stability and efficacy of semi-solid formulations. AI-driven predictive modeling is enhancing formulation optimization, reducing trial-and-error in development. The integration of continuous manufacturing processes is increasing production efficiency, reducing batch-to-batch variability, and ensuring better compliance with regulatory standards. Additionally, innovations in nano-emulsion technology are improving drug absorption and bioavailability in transdermal and dermatological applications. These technological advancements are making semi-solid dosage contract manufacturing more precise, scalable, and cost-effective.

Which Therapeutic Areas Are Driving Demand For Semi-Solid Dosage Contract Manufacturing?

The dermatology sector is a major driver of semi-solid contract manufacturing, with increasing demand for treatments for psoriasis, eczema, acne, and fungal infections. The transdermal drug delivery segment is also growing, with patients seeking non-invasive alternatives to oral and injectable medications. Hormone replacement therapy (HRT), pain management creams, and wound care products are further driving demand for contract manufacturing services. Additionally, the rise of over-the-counter (OTC) skincare and cosmeceutical products is expanding opportunities for CMOs specializing in semi-solid formulations.

What Factors Are Fueling The Growth Of The Semi-Solid Dosage Contract Manufacturing Market?

The growth of the semi-solid dosage contract manufacturing market is driven by increasing outsourcing trends in the pharmaceutical industry, rising demand for dermatological and transdermal treatments, and technological advancements in formulation science. Regulatory agencies such as the FDA and EMA are emphasizing stringent quality control and GMP compliance, prompting pharmaceutical companies to partner with specialized CMOs. Additionally, the expansion of generic and OTC pharmaceutical products is fueling demand for scalable and cost-effective manufacturing solutions. As innovation in semi-solid drug delivery continues, contract manufacturing will play an increasingly vital role in the pharmaceutical supply chain.

SCOPE OF STUDY:

The report analyzes the Semi-Solid Dosage Contract Manufacturing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Type (Topical, Transdermal, Oral); Product (Creams, Ointments, Gels, Lotions, Pastes, Others); End-Use (Pharmaceutical Companies, Cosmeceutical Companies, Others)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

• Aenova Group
• AGC Biologics
• Alcami Corporation
• Alchem Laboratories
• Almac Group
• Ascendia Pharmaceuticals
• Avid Bioservices
• Boehringer Ingelheim
• Bora Pharmaceuticals
• Cambrex Corporation
• Catalent, Inc.
• Contract Pharmaceuticals Limited
• DPT Laboratories, Ltd.
• Fermion Oy
• Hetero Labs Limited
• Hovione
• Ind-Swift Laboratories Ltd.
• LGM Pharma
• Lonza Group
• Pace Analytical Life Sciences, LLC
• Patheon N.V.
• Pfizer CentreOne
• Pierre Fabre Group
• Piramal Pharma Solutions
• Recipharm AB
• Rubicon Research Pvt. Ltd.
• Sharp Services
• The Lubrizol Corporation
• TriRx Pharmaceutical Services
• WuXi AppTec

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.